4-吡咯烷-1-基苯甲酰基氯化物 | 679809-11-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 4-吡咯烷-1-基苯甲酰基氯化物
• 英文名称: 4-(pyrrolidin-1-yl)benzoyl chloride
• 英文别名: 4-pyrrolidin-1-ylbenzoyl chloride
• CAS: 679809-11-1
• 化学式: C₁₁H₁₂ClNO
• 分子量: 209.675
• InChiKey: SUSRTAJMCHLIMG-UHFFFAOYSA-N

物化性质

• 沸点：
  339.2±25.0 °C(Predicted)
• 密度：
  1.230±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-吡咯烷-1-基苯甲酰基氯化物 在 吡啶 、 硫酸 、 铁粉 、 氯化铵 、 溶剂黄146 、 N,N-二异丙基乙胺 、 potassium hydroxide 作用下， 以 二氯甲烷 为溶剂， 反应 3.5h， 生成 2-methyl-8-(4-(pyrrolidin-1-yl)phenyl)chromeno[7,8-d]imidazol-6(1H)-one
  参考文献：
  名称：

  Optimization of a Small Tropomyosin-Related Kinase B (TrkB) Agonist 7,8-Dihydroxyflavone Active in Mouse Models of Depression

  摘要：

  Structure-activity relationship study shows that the catechol group in 7,8-dihdyroxyflavone, a selective small TrkB receptor agonist, is critical for agonistic activity. To improve the poor pharmacolcinetic profiles intrinsic to catechol-containing molecules and to elevate the agonistic effect of the lead compound, we initiated the lead optimization campaign by synthesizing various bioisosteric derivatives. Here we show that the optimized 2-methyl-8-(4'-(pyrrolidin-l-yl)phenyl)chromeno[7,8-d]imidazol-6(1H)-one derivative possesses enhanced TrkB stimulatory activity. Chronic oral administration of this compound significantly reduces the immobility in forced swim test and tail suspension test, two classical antidepressant behavioral animal models, which is accompanied by robust TrkB activation in hippocampus of mouse brain. Further, in vitro ADMET studies demonstrate that this compound possesses the improved features compared to the previous lead compound. Hence, this optimized compound may act as a promising lead candidate for in-depth drug development for treating various neurological disorders including depression.

  DOI：

  10.1021/jm301099x
• 作为产物：
  描述：

  4-(1-吡咯烷基)苯甲酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 生成 4-吡咯烷-1-基苯甲酰基氯化物
  参考文献：
  名称：

  对映选择性狄尔斯-α-（酰基硫代）丙烯醛的der醛反应：含硫手性季碳的一个新入口

  摘要：

  描述了由手性三胺的有机铵盐诱导的α-（氨基甲酰基硫基）丙烯醛的催化和对映选择性狄尔斯-阿尔德反应。α-（氨基甲酰硫基）丙烯醛首次设计和合成为新型的含硫双亲性生物。狄尔斯-阿尔德反应提供的手性叔硫醇前驱体的ee高达91％。

  DOI：

  10.1021/ol300921f

文献信息

• Benzoheterocyclic derivatives
  申请人：Otsuka Pharmaceuticals Co., Ltd.

  公开号：US06335327B1

  公开（公告）日：2002-01-01

  A benzoheterocyclic derivative of the following formula [1]: and pharmaceutically acceptable salts thereof, which show excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as a vasopressin antagonist, vasopressin agonist or oxytocin antagonist.

  以下是该句子的中文翻译： 一种苯并杂环衍生物，其化学式如下： 及其药用盐，表现出优异的抗加压素活性、加压素激动活性和催产素拮抗活性，可用作加压素拮抗剂、加压素激动剂或催产素拮抗剂。
• [EN] PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] ANTAGONISTES DE RECEPTEUR DE LA PROSTAGLANDINE D2 POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：MILLENNIUM PHARM INC

  公开号：WO2005100321A1

  公开（公告）日：2005-10-27

  Disclosed herein are compounds represented by Structural Formula: (I) and (I-A). Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply 'CRTH2' for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.

  本文披露了由结构式(I)和(I-A)表示的化合物。还披露了利用这些化合物抑制称为趋化剂受体同源分子表达在Th2上的G蛋白偶联受体，简称为'CRTH2'，用于治疗炎症性疾病。结构式(I)和(I-A)中的变量在此处被定义。
• Cesium Carboxylate-Promoted Iridium Catalyzed C–H Amidation/Cyclization with 2,2,2-Trichloroethoxycarbonyl Azide
  作者：Tao Zhang、Zhen Wang、Xuejiao Hu、Meng Yu、Tianning Deng、Guigen Li、Hongjian Lu

  DOI：10.1021/acs.joc.6b00818

  日期：2016.6.3

  An Ir(III)-catalyzed direct C–H amidation/cyclization of benzamides using 2,2,2-trichloroethoxycarbonyl azide (TrocN3) as the aminocarbonyl source is reported. With the aid of cesium carboxylate, the reactions proceed efficiently and with high regioselectivity, producing various functionalized quinazoline-2,4(1H,3H)-diones, which are important building blocks and key synthetic intermediates for biologically

  据报道，使用2,2,2-三氯乙氧羰基叠氮化物（TrocN 3）作为氨基羰基来源，Ir（III）催化苯甲酰胺的直接CH–H酰胺化/环化反应。在羧酸铯的帮助下，反应有效地进行并且具有高区域选择性，从而产生各种官能化的喹唑啉-2,4（1 H，3 H）-二酮，它们是重要的构建基块和重要的合成中间体，是生物学和医学上重要的化合物。在反应过程中，两个新的C–N键通过打破C–H和N–H键序列而形成。
• PGD2 receptor antagonists for the treatment of inflammatory diseases
  申请人：Ghosh Shomir

  公开号：US20050256158A1

  公开（公告）日：2005-11-17

  Disclosed herein are compounds represented by Structural Formula (I) and (I-A): Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply “CRTH2” for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.

  本文揭示了由结构式（I）和（I-A）表示的化合物：还披露了利用这些化合物抑制称为Th2表达的G蛋白偶联受体的化学引诱受体同源分子，简称“CRTH2”，用于治疗炎症性疾病。结构式（I）和（I-A）中的变量在此处被定义。
• [EN] HETEROCYCLIC FLAVONE DERIVATIVES, COMPOSITIONS, AND METHODS RELATED THERETO<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES DE FLAVONE, COMPOSITIONS ET PROCÉDÉS S'Y RAPPORTANT
  申请人：UNIV EMORY

  公开号：WO2014018741A1

  公开（公告）日：2014-01-30

  In certain embodiments, the disclosure relates to heterocyclic flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of 5 treating or preventing diseases or conditions related to BDNF and TrkB activity, such as depression, stroke, Rett syndrome, Parkinson's disease, and Alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof.

  在某些实施例中，该公开涉及杂环黄酮衍生物，例如本文提供的公式所描述的那些，药物组合物以及相关方法。在某些实施例中，该公开涉及治疗或预防与BDNF和TrkB活性相关的疾病或症状的方法，例如抑郁症、中风、雷特综合征、帕金森病和阿尔茨海默病，通过向需要的受试者施用包含本文所披露的化合物的药物组合物的有效剂量。